Atlas Trials

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Clinical trial NCT06378892 · RECRUITING

Trial details

NCT number
NCT06378892
Sponsor
Centro di Riferimento Oncologico - Aviano
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Start date
2024-03-15
Primary completion
2028-05-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.